Advertisement

Topics

UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq

06:37 EDT 23 Sep 2016 | Pharmaceutical Business Review

The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharmaceuticals’ Strensiq (asfotase alfa) drug to treat rare inherited bone disorder in children.

Original Article: UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq

NEXT ARTICLE

More From BioPortfolio on "UK’s NICE supports restricted use of Alexion Pharmaceuticals' Strensiq"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...